
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis is expected to experience some headwinds due to changes in FDA device classifications, which may result in pricing pressure and market share decline. However, the company has a diversified portfolio and has outperformed the market in multiple categories, making it a Buy with a target price of $41. With future growth expected in the global orthopedic market, Enovis's strategic acquisitions and focus on reducing debt make it a strong contender in the industry.
Bears say
Enovis is a medical technology company with a majority of its revenue coming from the Prevention & Recovery segment. Despite consistently delivering above-market growth and expanding into new product offerings, Enovis's shares are currently trading at a discount to its peers, which we believe is unwarranted. We expect Enovis to continue generating strong growth, optimizing its portfolio, and improving its financials, which should support an increase in its valuation multiple. While there are risks of competition, seasonality, and existing debt, we see Enovis as an attractive value asset with potential for steady performance and share returns.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares